

# Robert J Motzer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/921299/publications.pdf>

Version: 2024-02-01

467  
papers

85,370  
citations

807

118  
h-index

381

280  
g-index

474  
all docs

474  
docs citations

474  
times ranked

39166  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.  | 9.4  | 110       |
| 2  | First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.   | 0.9  | 33        |
| 3  | Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. <i>Acta Oncologica</i> , 2022, 61, 52-57.  | 0.8  | 0         |
| 4  | Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.  | 2.3  | 248       |
| 5  | Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 292-303. | 5.1  | 42        |
| 6  | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. <i>Cell</i> , 2022, 185, 563-575.e11.   | 13.5 | 223       |
| 7  | Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.   | 0.9  | 22        |
| 8  | Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.             | 3.4  | 75        |
| 9  | Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non-Clear-Cell Renal Cell Carcinoma and Genomic Correlates. <i>Journal of Clinical Oncology</i> , 2022, 40, 2333-2341.  | 0.8  | 72        |
| 10 | Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.  |      | 45        |
| 11 | Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. <i>European Urology Focus</i> , 2022, 8, 1278-1288.  | 1.6  | 11        |
| 12 | Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1929-1938.  | 0.8  | 33        |
| 13 | Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 383-400.   | 1.1  | 20        |
| 14 | Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.  | 2.0  | 103       |
| 15 | Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 768-780.    | 5.1  | 23        |
| 16 | Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.   | 3.2  | 24        |
| 17 | Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2022, 20, .  | 0.1  | 0         |
| 18 | Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.        | 5.1  | 114       |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.   | 7.7  | 7         |
| 20 | Matched Molecular Profiling of Cell-Free DNA and Tumor Tissue in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>JCO Precision Oncology</i> , 2022, , .  | 1.5  | 3         |
| 21 | Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 4045-4055.  | 3.2  | 12        |
| 22 | Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. <i>European Urology</i> , 2021, 79, 659-662.     | 0.9  | 64        |
| 23 | Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. <i>Future Oncology</i> , 2021, 17, 403-409.  | 1.1  | 1         |
| 24 | Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2021, 124, 237-246.  | 2.9  | 10        |
| 25 | Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1371-1380.                      | 3.2  | 49        |
| 26 | Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 78-86.  | 3.2  | 154       |
| 27 | Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.  | 1.6  | 28        |
| 28 | Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO+IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2021, 39, 313-313. | 0.8  | 8         |
| 29 | Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. <i>European Urology</i> , 2021, 79, 334-338.                       | 0.9  | 39        |
| 30 | Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 829-841.  | 13.9 | 961       |
| 31 | A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.  | 1.2  | 3         |
| 32 | Four Cycles of Etoposide plus Cisplatin for Patients with Good-Risk Advanced Germ Cell Tumors. <i>Oncologist</i> , 2021, 26, 483-491.   | 1.9  | 8         |
| 33 | Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2910-2919.   | 3.2  | 45        |
| 34 | Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.   | 13.9 | 956       |
| 35 | High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab. <i>Molecular Cancer Research</i> , 2021, 19, 1510-1521.   | 1.5  | 20        |
| 36 | Lenvatinib (LEN) + pembrolizumab (PEMBRO) treatment in patients (pts) with metastatic clear cell renal cell carcinoma (RCC): Final results of a phase 1b/2 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, e16542-e16542.                         | 0.8  | 0         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4501-4501. | 0.8 | 30        |
| 38 | Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.   | 0.9 | 20        |
| 39 | Single-cell sequencing links multiregional immune landscapes and tissue-resident TÂcells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.   | 7.7 | 179       |
| 40 | Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e178-e183.  | 0.9 | 2         |
| 41 | Lenvatinib plus pembrolizumab in patients with either treatment-naïve or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. <i>Lancet Oncology</i> , The, 2021, 22, 946-958.  | 5.1 | 100       |
| 42 | Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.   | 3.2 | 12        |
| 43 | Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.  | 2.0 | 12        |
| 44 | Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.   | 1.1 | 10        |
| 45 | Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma. <i>European Urology Open Science</i> , 2021, 31, 1-9.  | 0.2 | 2         |
| 46 | Prognosis of Incidental Brain Metastases in Patients With Advanced Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 432-438.   | 2.3 | 19        |
| 47 | Germline Variants Identified in Patients with Early-onset Renal Cell Carcinoma Referred for Germline Genetic Testing. <i>European Urology Oncology</i> , 2021, 4, 993-1000.  | 2.6 | 16        |
| 48 | Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.   | 3.2 | 25        |
| 49 | Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 12-19.  | 0.6 | 39        |
| 50 | The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. <i>Acta OncolÂgica</i> , 2020, 59, 20-27.   | 0.8 | 3         |
| 51 | Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. <i>Kidney Cancer</i> , 2020, 4, 29-39.   | 0.2 | 2         |
| 52 | Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 283-293.  | 5.1 | 121       |
| 53 | Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2020, 126, 1-10.   | 1.3 | 19        |
| 54 | The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.   | 2.6 | 20        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 55 | Efficacy of Nivolumab plus Ipilimumab According to Number of IMDC Risk Factors in CheckMate 214. <i>European Urology</i> , 2020, 77, 449-453.  | 0.9  | 52        |
| 56 | Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.  | 1.9  | 76        |
| 57 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.     |      | 160       |
| 58 | Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. <i>Cancer</i> , 2020, 126, 4156-4167.                   | 2.0  | 201       |
| 59 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. <i>ESMO Open</i> , 2020, 5, e001079.                               | 2.0  | 343       |
| 60 | Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. <i>Cancer</i> , 2020, 126, 5247-5255.                           | 2.0  | 22        |
| 61 | Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. <i>Nature Medicine</i> , 2020, 26, 1733-1741.   | 15.2 | 282       |
| 62 | A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.  | 5.8  | 46        |
| 63 | Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. <i>Cancer Cell</i> , 2020, 38, 803-817.e4.  | 7.7  | 262       |
| 64 | Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma. <i>Future Oncology</i> , 2020, 16, 1199-1210.  | 1.1  | 4         |
| 65 | Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4863-4868.      | 3.2  | 14        |
| 66 | Adjuvant Chemotherapy With Etoposide Plus Cisplatin for Patients With Pathologic Stage II Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1332-1337.   | 0.8  | 11        |
| 67 | DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy. , 2020, 8, e000230.  |      | 37        |
| 68 | An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E625-E630.  | 0.3  | 1         |
| 69 | Systemic therapy for advanced clear cell renal cell carcinoma after discontinuation of immune-oncology and VEGF targeted therapy combinations. <i>BMC Urology</i> , 2020, 20, 84.  | 0.6  | 12        |
| 70 | Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101. <i>Cancer Science</i> , 2020, 111, 907-923.  | 1.7  | 33        |
| 71 | Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 1154-1163.              | 0.8  | 276       |
| 72 | Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514. | 3.2  | 20        |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 73 | Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.  | 1.3  | 19        |
| 74 | Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.   | 3.2  | 30        |
| 75 | PTEN Expression, Not Mutation Status in <i>TSC1</i> , <i>TSC2</i> , or <i>mTOR</i> , Correlates with the Outcome on Everolimus in Patients with Renal Cell Carcinoma Treated on the Randomized RECORD-3 Trial. <i>Clinical Cancer Research</i> , 2019, 25, 506-514. | 3.2  | 31        |
| 76 | Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , 2019, 20, 1370-1385.                 | 5.1  | 594       |
| 77 | A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 356-365.e1.  | 0.9  | 11        |
| 78 | PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.           | 3.2  | 50        |
| 79 | Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2019, 2, 505-514.   | 2.6  | 50        |
| 80 | Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.  | 0.8  | 6         |
| 81 | irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 2174-2184.                               | 3.2  | 80        |
| 82 | Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.  | 1.1  | 40        |
| 83 | Mucinous Tubular and Spindle-Cell Carcinoma of the Kidney: Clinical Features, Genomic Profiles, and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 268-274.e1.  | 0.9  | 29        |
| 84 | Impact of Teratoma on the Cumulative Incidence of Disease-Related Death in Patients With Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 2329-2337.  | 0.8  | 17        |
| 85 | Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , 2019, 393, 2404-2415.                          | 6.3  | 778       |
| 86 | Towards individualized therapy for metastatic renal cell carcinoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 621-633.  | 12.5 | 148       |
| 87 | Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e678-e688.  | 0.9  | 41        |
| 88 | Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1103-1115.   | 13.9 | 1,824     |
| 89 | COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 425-435.e4.   | 0.9  | 11        |
| 90 | The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)., 2019, 7, 354.   |      | 182       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.   | 0.9 | 12        |
| 92  | Comprehensive Genomic Analysis of Metastatic Non-“Clear-Cell Renal Cell Carcinoma to Identify Therapeutic Targets. <i>JCO Precision Oncology</i> , 2019, 3, 1-18.  | 1.5 | 7         |
| 93  | Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis. <i>Clinical Cancer Research</i> , 2019, 25, 1165-1173.  | 3.2 | 23        |
| 94  | Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. <i>Cancer Discovery</i> , 2019, 9, 510-525.   | 7.7 | 169       |
| 95  | Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.  | 9.4 | 2,702     |
| 96  | Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 297-310.  | 5.1 | 207       |
| 97  | Systemic Treatment of Metastatic Clear Cell Renal Cell Carcinoma in 2018: Current Paradigms, Use of Immunotherapy, and Future Directions. <i>European Urology</i> , 2019, 75, 100-110.   | 0.9 | 178       |
| 98  | Combination therapy for advanced and metastatic kidney cancer. <i>Nature Reviews Urology</i> , 2019, 16, 77-78.  | 1.9 | 3         |
| 99  | Surgical Management of Patients with Advanced Germ Cell Tumors Following Salvage Chemotherapy: Memorial Sloan Kettering Cancer Center (MSKCC) Experience.. <i>Urology</i> , 2019, 124, 174-178.  | 0.5 | 6         |
| 100 | Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2019, 5, 642-649.   | 1.6 | 40        |
| 101 | Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 12-17.   | 0.8 | 25        |
| 102 | Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 101-101.  | 0.8 | 75        |
| 103 | CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4513-4513.   | 0.8 | 61        |
| 104 | Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 547-547.   | 0.8 | 49        |
| 105 | Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564. | 0.8 | 10        |
| 106 | Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.  | 0.8 | 14        |
| 107 | NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.   | 2.3 | 185       |
| 108 | Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen. <i>Urology</i> , 2018, 114, 133-138.   | 0.5 | 12        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 109 | Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study. <i>Clinical Cancer Research</i> , 2018, 24, 1554-1561.   | 3.2  | 34        |
| 110 | Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 3005-3013.  | 3.2  | 48        |
| 111 | Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. <i>Science</i> , 2018, 359, 801-806.  | 6.0  | 898       |
| 112 | RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis. <i>BMC Cancer</i> , 2018, 18, 195.  | 1.1  | 3         |
| 113 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 298-304.   | 0.9  | 41        |
| 114 | Histologic and Oncologic Outcomes Following Liver Mass Resection With Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Germ Cell Tumor. <i>Urology</i> , 2018, 118, 114-118.  | 0.5  | 7         |
| 115 | Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. <i>European Journal of Cancer</i> , 2018, 94, 87-94.  | 1.3  | 31        |
| 116 | Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.   | 13.9 | 3,334     |
| 117 | Long-Term Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma: A Pooled Analysis of Clinical Trials. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 6-12.e4.   | 0.9  | 11        |
| 118 | Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.   | 1.6  | 29        |
| 119 | Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>European Urology</i> , 2018, 73, 62-68.   | 0.9  | 164       |
| 120 | Reply to Francesco Massari, Vincenzo Di Nunno, and Andrea Ardizoni's Letter to the Editor re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. <i>Eur Urol</i> 2018;73:62-8. <i>European Urology</i> , 2018, 73, e73. | 0.9  | 1         |
| 121 | Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.   | 0.8  | 43        |
| 122 | Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 765-772.   | 0.8  | 117       |
| 123 | Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2018, 19, 1688-1698.  | 5.1  | 119       |
| 124 | Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 911-912.   | 2.9  | 6         |
| 125 | Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.  | 2.9  | 66        |
| 126 | Validation of the 16-Gene Recurrence Score in Patients with Locoregional, High-Risk Renal Cell Carcinoma from a Phase III Trial of Adjuvant Sunitinib. <i>Clinical Cancer Research</i> , 2018, 24, 4407-4415.   | 3.2  | 50        |



| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 127 | Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e317-e326.   | 5.1  | 46        |
| 128 | Phase I Trials of Anti-ENPP3 Antibody-Drug Conjugates in Advanced Refractory Renal Cell Carcinomas. <i>Clinical Cancer Research</i> , 2018, 24, 4399-4406.   | 3.2  | 44        |
| 129 | Immune Checkpoint Blockade in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 379, 91-93.  | 13.9 | 11        |
| 130 | Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2018, 4, 1228.  | 3.4  | 132       |
| 131 | Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 118, 1176-1178.  | 2.9  | 54        |
| 132 | Safety of pazopanib and sunitinib in treatment-naïve patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial. <i>Journal of Hematology and Oncology</i> , 2018, 11, 69.                   | 6.9  | 32        |
| 133 | Important Group Differences on the Functional Assessment of Cancer Therapy-Kidney Symptom Index Disease-Related Symptoms in Patients with Metastatic Renal Cell Carcinoma. <i>Value in Health</i> , 2018, 21, 1413-1418.                       | 0.1  | 7         |
| 134 | The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018, 6, 758-765.  | 1.6  | 89        |
| 135 | The role of tivozanib in advanced renal cell carcinoma therapy. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1113-1124.  | 1.1  | 14        |
| 136 | Cytoreductive Nephrectomy - Patient Selection Is Key. <i>New England Journal of Medicine</i> , 2018, 379, 481-482.   | 13.9 | 88        |
| 137 | Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.  | 15.2 | 900       |
| 138 | Correlation of degree of tumor immune infiltration and insertion-and-deletion (indel) burden with outcome on programmed death 1 (PD1) therapy in advanced renal cell cancer (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4518-4518. | 0.8  | 18        |
| 139 | A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate Tj ETQq1 1 0.784314 rgB2p Overlo                | 13.9 | 88        |
| 140 | CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS4601-TPS4601.      | 0.8  | 11        |
| 141 | IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.  | 0.8  | 164       |
| 142 | The evolution of anti-angiogenic therapy for kidney cancer. <i>Nature Reviews Nephrology</i> , 2017, 13, 69-70.  | 4.1  | 19        |
| 143 | Systemic Therapy for Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 354-366.   | 13.9 | 940       |
| 144 | Germline Genetic Biomarkers of Sunitinib Efficacy in Advanced Renal Cell Carcinoma: Results From the RENAL EFFECT Trial. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 526-533.   | 0.9  | 8         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 145 | CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.   | 0.9 | 199       |
| 146 | Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 639-646.  | 0.6 | 51        |
| 147 | Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.   | 0.9 | 209       |
| 148 | Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 532.e7-532.e13. | 0.8 | 25        |
| 149 | Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e987-e994.   | 0.9 | 39        |
| 150 | Bilateral Testicular Germ Cell Tumors in the Era of Multimodal Therapy. <i>Urology</i> , 2017, 103, 154-160.  | 0.5 | 12        |
| 151 | Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 804-834.   | 2.3 | 443       |
| 152 | Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 825.                | 3.8 | 366       |
| 153 | Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2017, 71, 405-414.   | 0.9 | 173       |
| 154 | Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors. <i>Journal of Urology</i> , 2017, 197, 391-397.   | 0.2 | 10        |
| 155 | Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2017, 22, 41-52.  | 1.9 | 61        |
| 156 | Tumor Xenografts of Human Clear Cell Renal Cell Carcinoma But Not Corresponding Cell Lines Recapitulate Clinical Response to Sunitinib: Feasibility of Using Biopsy Samples. <i>European Urology Focus</i> , 2017, 3, 590-598.                              | 1.6 | 31        |
| 157 | Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma. <i>European Urology Focus</i> , 2017, 3, 421-427.   | 1.6 | 43        |
| 158 | Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3916-3923.   | 0.8 | 316       |
| 159 | Abstract 1771: Phase 3 trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma: exploratory molecular analysis of tumor biomarkers. , 2017, , .   |     | 1         |
| 160 | A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2017, 35, 431-431.                             | 0.8 | 59        |
| 161 | Immune Checkpoint Therapy in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2016, 22, 92-95.  | 1.0 | 35        |
| 162 | Validation and genomic interrogation of the <sc><i>MET</i></sc> variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. <i>Cancer</i> , 2016, 122, 402-410.   | 2.0 | 18        |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 163 | Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. <i>Cancer</i> , 2016, 122, 1108-1115.  | 2.0  | 34        |
| 164 | Pelvic Lymph Node Dissection in Patients Treated for Testis Cancer: The Memorial Sloan Kettering Cancer Center Experience. <i>Urology</i> , 2016, 95, 128-131.  | 0.5  | 6         |
| 165 | Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.  | 0.8  | 31        |
| 166 | Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. <i>JAMA Oncology</i> , 2016, 2, 1179.   | 3.4  | 154       |
| 167 | Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2016, 114, 642-649.  | 2.9  | 43        |
| 168 | Treatment of Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2016, 374, 888-890.  | 13.9 | 22        |
| 169 | A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma. <i>Future Oncology</i> , 2016, 12, 175-182.  | 1.1  | 21        |
| 170 | Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 3846-3853.  | 0.8  | 69        |
| 171 | Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. <i>New England Journal of Medicine</i> , 2016, 375, 2246-2254.  | 13.9 | 640       |
| 172 | Perspective: What next for treatment?. <i>Nature</i> , 2016, 537, S111-S111.  | 13.7 | 25        |
| 173 | Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets. <i>Nature Communications</i> , 2016, 7, 13131.  | 5.8  | 140       |
| 174 | Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1251-1269.                           | 1.6  | 29        |
| 175 | Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 917-927.  | 5.1  | 789       |
| 176 | Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 994-1003.   | 5.1  | 194       |
| 177 | Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma. <i>Nature Reviews Urology</i> , 2016, 13, 420-431.   | 1.9  | 78        |
| 178 | Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 406-414. | 0.9  | 8         |
| 179 | A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2016, 21, 787-788d.                                  | 1.9  | 84        |
| 180 | Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma. <i>Lancet Oncology</i> , The, 2016, 17, e4-e5.   | 5.1  | 103       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 181 | Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 56-62.  | 0.9 | 7         |
| 182 | Renal cell carcinoma: A nomogram for the CT imaging-inclusive prediction of indolent, non-clear cell renal cortical tumours. <i>European Journal of Cancer</i> , 2016, 59, 57-64.  | 1.3 | 15        |
| 183 | Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. <i>Oncology</i> , 2016, 90, 119-126.   | 0.9 | 8         |
| 184 | Randomized Open-Label Phase II Trial of Apatolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 1660-1668. | 0.8 | 99        |
| 185 | Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4). <i>Annals of Oncology</i> , 2016, 27, 441-448.   | 0.6 | 31        |
| 186 | Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2016, 43, 95-104.   | 0.8 | 9         |
| 187 | Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib. <i>Targeted Oncology</i> , 2016, 11, 229-234.   | 1.7 | 17        |
| 188 | Long-term Safety of Sunitinib in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2016, 69, 345-351.   | 0.9 | 53        |
| 189 | Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.   | 2.3 | 198       |
| 190 | The Right Drug for the Right Patient: Navigating Systemic Therapy Options in Metastatic Renal Cell Carcinoma and Future Directions. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1168-1170.                                      | 2.3 | 2         |
| 191 | Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799.   | 2.3 | 98        |
| 192 | Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 328-337.e3.                                 | 0.9 | 28        |
| 193 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. <i>Lancet Oncology</i> , The, 2015, 16, 1473-1482.   | 5.1 | 762       |
| 194 | Development and Validation of a Prognostic Nomogram for Progression-Free Survival in Patients with Advanced Renal Cell Carcinoma Treated with Pazopanib. <i>Oncology</i> , 2015, 89, 235-241.  | 0.9 | 9         |
| 195 | Long-Term Survival Rates after Resection for Locally Advanced Kidney Cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 Experience. <i>Journal of Urology</i> , 2015, 193, 1911-1917.   | 0.2 | 40        |
| 196 | Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 453-460.    | 0.9 | 5         |
| 197 | Sunitinib as a paradigm for tyrosine kinase inhibitor development for renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 275-279.  | 0.8 | 7         |
| 198 | Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077.                   | 3.2 | 217       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 199 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.  | 13.9 | 1,004     |
| 200 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.   | 13.9 | 4,889     |
| 201 | Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. <i>British Journal of Cancer</i> , 2015, 113, 1571-1580.   | 2.9  | 88        |
| 202 | Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 540-547.e7.   | 0.9  | 22        |
| 203 | Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.  | 0.8  | 914       |
| 204 | A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.  | 0.9  | 122       |
| 205 | Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 59-66.  | 0.9  | 32        |
| 206 | Rates of Teratoma and Viable Cancer at Post-Chemotherapy Retroperitoneal Lymph Node Dissection after Induction Chemotherapy for Good Risk Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2015, 193, 513-518.  | 0.2  | 20        |
| 207 | Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.  | 1.7  | 45        |
| 208 | Identification of efficacy biomarkers in a large metastatic renal cell carcinoma (mRCC) cohort through next generation sequencing (NGS): Results from RECORD-3.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4509-4509.  | 0.8  | 14        |
| 209 | CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4578-TPS4578.                     | 0.8  | 24        |
| 210 | Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.   | 2.3  | 9         |
| 211 | Continuing a Cancer Treatment Despite Tumor Growth May Be Valuable: Sunitinib in Renal Cell Carcinoma as Example. <i>PLoS ONE</i> , 2014, 9, e96316.   | 1.1  | 26        |
| 212 | From molecular understanding to clinical advances. <i>Nature Reviews Urology</i> , 2014, 11, 77-79.  | 1.9  | 0         |
| 213 | Radiogenomics of Clear Cell Renal Cell Carcinoma: Associations between CT Imaging Features and Mutations. <i>Radiology</i> , 2014, 270, 464-471.   | 3.6  | 226       |
| 214 | Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2014, 120, 1871-1880.  | 2.0  | 19        |
| 215 | Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. <i>Cancer Medicine</i> , 2014, 3, 1353-1358.   | 1.3  | 8         |
| 216 | Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 739-750. | 1.1  | 69        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 217 | Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib. <i>New England Journal of Medicine</i> , 2014, 370, 1769-1770.   | 13.9 | 251       |
| 218 | Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 1955-1964.   | 3.2  | 208       |
| 219 | Impact of Recurrent Copy Number Alterations and Cancer Gene Mutations on the Predictive Accuracy of Prognostic Models in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 24-29.  | 0.2  | 15        |
| 220 | Circulating proteins as potential biomarkers of sunitinib and interferon- $\gamma$ efficacy in treatment-naïve patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 151-161.   | 1.1  | 52        |
| 221 | A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC). <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 181-189.                         | 1.1  | 83        |
| 222 | Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 760-767.  | 0.8  | 331       |
| 223 | Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 351-358.  | 1.3  | 113       |
| 224 | Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. <i>European Journal of Cancer</i> , 2014, 50, 2162-2170. | 1.3  | 82        |
| 225 | Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2765-2772.           | 0.8  | 355       |
| 226 | Clinical Outcomes of Local and Metastatic Testicular Sex Cord-Stromal Tumors. <i>Journal of Urology</i> , 2014, 192, 415-419.  | 0.2  | 49        |
| 227 | Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 286-296.   | 5.1  | 239       |
| 228 | The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. <i>Cancer Medicine</i> , 2014, 3, 1485-1492.   | 1.3  | 110       |
| 229 | Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.   | 2.3  | 56        |
| 230 | Genome-wide association study (GWAS) of efficacy and safety endpoints in pazopanib- or sunitinib-treated patients with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4503-4503.   | 0.8  | 7         |
| 231 | A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.  | 0.8  | 12        |
| 232 | A phase 2 multicenter study of tivatinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.   | 1.2  | 41        |
| 233 | Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2013, 369, 722-731.  | 13.9 | 1,648     |
| 234 | Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma. <i>Cell Reports</i> , 2013, 3, 277-281.   | 2.9  | 32        |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 235 | Clinical and Pathologic Impact of Select Chromatin-modulating Tumor Suppressors in Clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2013, 63, 848-854.   | 0.9  | 198       |
| 236 | Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 297-302.   | 0.9  | 46        |
| 237 | Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma Treated With Axitinib. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 107-114.   | 0.9  | 42        |
| 238 | Systemic Treatment Options for Untreated Patients With Metastatic Clear Cell Renal Cancer. <i>Seminars in Oncology</i> , 2013, 40, 436-443.  | 0.8  | 20        |
| 239 | Survival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial. <i>European Urology</i> , 2013, 64, 994-1002.   | 0.9  | 30        |
| 240 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 552-562.                        | 5.1  | 640       |
| 241 | Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 3791-3799.   | 0.8  | 388       |
| 242 | An Epidemiologic and Genomic Investigation Into the Obesity Paradox in Renal Cell Carcinoma. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1862-1870.   | 3.0  | 231       |
| 243 | Intra- and Interobserver Variability in CT Measurements in Oncology. <i>Radiology</i> , 2013, 269, 451-459.  | 3.6  | 83        |
| 244 | Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2013, 108, 2470-2477.  | 2.9  | 121       |
| 245 | Pazopanib versus Sunitinib in Renal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1968-1970.   | 13.9 | 43        |
| 246 | Novel Approaches Targeting the Vascular Endothelial Growth Factor Axis in Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass )</i> , 2013, 19, 299-306.  | 1.0  | 9         |
| 247 | Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older. <i>Cancer</i> , 2013, 119, 2574-2581.   | 2.0  | 30        |
| 248 | Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 491-504.   | 1.0  | 122       |
| 249 | Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators <i>BAP1</i> and <i>SETD2</i> : A Report by MSKCC and the KIRC TCGA Research Network. <i>Clinical Cancer Research</i> , 2013, 19, 3259-3267. | 3.2  | 301       |
| 250 | Analyzing the Pivotal Trial That Compared Sunitinib and IFN- $\gamma$ in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth. <i>Clinical Cancer Research</i> , 2012, 18, 2374-2381.                              | 3.2  | 56        |
| 251 | Randomized Phase II Trial of Sunitinib on an Intermittent Versus Continuous Dosing Schedule As First-Line Therapy for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1371-1377.                              | 0.8  | 254       |
| 252 | Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 502-535.   | 2.3  | 71        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 253 | Tumor Control Outcomes After Hypofractionated and Single-Dose Stereotactic Image-Guided Intensity-Modulated Radiotherapy for Extracranial Metastases From Renal Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1744-1748.  | 0.4 | 199       |
| 254 | Improvement in Overall Survival of Patients with Advanced Renal Cell Carcinoma: Prognostic Factor Trend Analysis from an International Data Set of Clinical Trials. <i>Journal of Urology</i> , 2012, 188, 2095-2100.  | 0.2 | 35        |
| 255 | Body Mass Index Is Associated With Higher Lymph Node Counts During Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2012, 79, 361-364.  | 0.5 | 16        |
| 256 | Clinical Impact of Residual Extraretroperitoneal Masses in Patients With Advanced Nonseminomatous Germ Cell Testicular Cancer. <i>Urology</i> , 2012, 79, 156-159.   | 0.5 | 28        |
| 257 | Outcomes in Patients With Clinical Stage III NSGCT Who Achieve Complete Clinical Response to Chemotherapy at Extraretroperitoneal Disease Site. <i>Urology</i> , 2012, 79, 1079-1084.  | 0.5 | 5         |
| 258 | Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial. <i>BMC Cancer</i> , 2012, 12, 311.  | 1.1 | 30        |
| 259 | Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2012, 118, 1868-1876.   | 2.0 | 109       |
| 260 | Clinical and histopathologic characteristics of rash in cancer patients treated with mammalian target of rapamycin inhibitors. <i>Cancer</i> , 2012, 118, 5078-5083.   | 2.0 | 33        |
| 261 | Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.  | 0.9 | 59        |
| 262 | Reply to Giuseppe Procopio, Elena Verzoni and Filippo De Braud's Letter to the Editor re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and Safety of Everolimus in Elderly Patients with Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>Eur Urol</i> 2012;61:826-33. <i>European Urology</i> , 2012, 62, e7-e8. | 0.9 | 0         |
| 263 | Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). <i>BJU International</i> , 2012, 110, 1276-1282.   | 1.3 | 30        |
| 264 | Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: Endpoints for clinical trial design. <i>Cancer</i> , 2012, 118, 981-986.   | 2.0 | 50        |
| 265 | Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2012, 30, 335-340.   | 1.2 | 79        |
| 266 | Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. <i>Oncologist</i> , 2011, 16, 45-50.  | 1.9 | 79        |
| 267 | Clinical Characteristics and Outcomes of Patients With Recurrence 5 Years After Nephrectomy for Localized Renal Cell Carcinoma. <i>Journal of Urology</i> , 2011, 185, 433-438.  | 0.2 | 79        |
| 268 | mTOR Inhibitors in Advanced Renal Cell Carcinoma. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 835-852.   | 0.9 | 112       |
| 269 | A Review of Second-line Chemotherapy and Prognostic Models for Disseminated Germ Cell Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 557-576.   | 0.9 | 16        |
| 270 | Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1287-1298.  | 1.3 | 133       |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 271 | Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node Dissection. <i>Urology</i> , 2011, 77, 368-372.   | 0.5 | 14        |
| 272 | Outcomes After Resection of Postchemotherapy Residual Neck Mass in Patients With Germ Cell Tumors—An Update. <i>Urology</i> , 2011, 77, 655-659.   | 0.5 | 10        |
| 273 | Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. <i>Lancet</i> , The, 2011, 378, 1931-1939.   | 6.3 | 1,663     |
| 274 | Sarcomatoid-variant Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 454-459.  | 0.6 | 91        |
| 275 | Resection of Primary Mediastinal Non-Seminomatous Germ Cell Tumors: A 28-Year Experience at Memorial Sloan-Kettering Cancer Center. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1236-1241.  | 0.5 | 42        |
| 276 | NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, S-1-S-29.   | 2.3 | 48        |
| 277 | Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 960-977.  | 2.3 | 90        |
| 278 | Sequelae of Treatment in Long-term Survivors of Testis Cancer. <i>European Urology</i> , 2011, 60, 516-526.  | 0.9 | 70        |
| 279 | ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of Metastatic Disease. <i>European Urology</i> , 2011, 60, 684-690.   | 0.9 | 125       |
| 280 | Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib. <i>Medical Oncology</i> , 2011, 28, 1527-1529.   | 1.2 | 16        |
| 281 | Patient-Reported Outcomes in a Phase III Study of Everolimus Versus Placebo in Patients with Metastatic Carcinoma of the Kidney That Has Progressed on Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy. <i>Oncologist</i> , 2011, 16, 632-640. | 1.9 | 26        |
| 282 | Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2011, 103, 763-773.   | 3.0 | 526       |
| 283 | New Perspectives on the Treatment of Metastatic Renal Cell Carcinoma: An Introduction and Historical Overview. <i>Oncologist</i> , 2011, 16, 1-3.  | 1.9 | 29        |
| 284 | Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. <i>Clinical Cancer Research</i> , 2011, 17, 5443-5450.   | 3.2 | 164       |
| 285 | High-dose chemotherapy and stem cell transplantation for advanced testicular cancer. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 1093-1105.   | 1.1 | 16        |
| 286 | Research and innovation in the development of everolimus for oncology. <i>Expert Opinion on Drug Discovery</i> , 2011, 6, 323-338.   | 2.5 | 24        |
| 287 | Phase I/II Trial of Sunitinib Plus Gefitinib in Patients With Metastatic Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2010, 33, 614-618.   | 0.6 | 26        |
| 288 | Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 357-371.                                     | 1.1 | 428       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 289 | Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2010, 28, 523-528.  | 1.2 | 66        |
| 290 | Stage migration and increasing proportion of favorable prognosis metastatic renal cell carcinoma patients. <i>Cancer</i> , 2010, 116, 347-354.   | 2.0 | 46        |
| 291 | Phase 3 trial of everolimus for metastatic renal cell carcinoma. <i>Cancer</i> , 2010, 116, 4256-4265.   | 2.0 | 1,039     |
| 292 | Evaluation of lymph node counts in primary retroperitoneal lymph node dissection. <i>Cancer</i> , 2010, 116, 5243-5250.  | 2.0 | 25        |
| 293 | Reply to L.H. Einhorn et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e740-e740.  | 0.8 | 1         |
| 294 | Weighing Risks and Benefits of Postchemotherapy Retroperitoneal Lymph Node Dissection: Not So Easy. <i>Journal of Clinical Oncology</i> , 2010, 28, 519-521.   | 0.8 | 14        |
| 295 | TI-CE High-Dose Chemotherapy for Patients With Previously Treated Germ Cell Tumors: Results and Prognostic Factor Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 1706-1713.                             | 0.8 | 192       |
| 296 | Genomic Deregulation during Metastasis of Renal Cell Carcinoma Implements a Myofibroblast-Like Program of Gene Expression. <i>Cancer Research</i> , 2010, 70, 9682-9692.   | 0.4 | 31        |
| 297 | Reply to B.I. Rini et al. <i>Journal of Clinical Oncology</i> , 2010, 28, e286-e287.   | 0.8 | 4         |
| 298 | Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 396-403.                                      | 2.5 | 202       |
| 299 | The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular Cancer. <i>Urology</i> , 2010, 75, 1431-1435.                                       | 0.5 | 47        |
| 300 | Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1432-1439.  | 0.8 | 298       |
| 301 | Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa. <i>Journal of Oncology Practice</i> , 2009, 5, 66-70.           | 2.5 | 32        |
| 302 | Targeting Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3274-3276.   | 0.8 | 68        |
| 303 | Phase I Trial of Sunitinib Malate plus Interferon- $\gamma$ for Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 28-33.  | 0.9 | 62        |
| 304 | Good-risk-advanced germ cell tumors: historical perspective and current standards of care. <i>World Journal of Urology</i> , 2009, 27, 463-470.  | 1.2 | 10        |
| 305 | Using the Rasch Model to Validate and Enhance the Interpretation of the Functional Assessment of Cancer Therapy "Kidney Symptom Index" Disease-Related Symptoms Scale. <i>Value in Health</i> , 2009, 12, 580-586. | 0.1 | 7         |
| 306 | Phase I Study Combining Treatment with Temsirolimus and Sunitinib Malate in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 24-27.                                    | 0.9 | 148       |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 307 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 3584-3590.          | 0.8 | 2,020     |
| 308 | Kidney Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 618-630.  | 2.3 | 249       |
| 309 | Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 672-693.  | 2.3 | 103       |
| 310 | Sunitinib and Axitinib in Renal Cell Carcinoma. , 2009, , 151-165.   |     | 0         |
| 311 | Targeted Therapy for Metastatic Renal Cell Carcinoma: Overview. , 2009, , 1-12.  |     | 0         |
| 312 | Phase II trial of lenalidomide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2008, 26, 273-276.   | 1.2 | 17        |
| 313 | The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor. <i>Cancer</i> , 2008, 112, 800-805.  | 2.0 | 22        |
| 314 | Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2008, 113, 1552-1558.  | 2.0 | 184       |
| 315 | Expression of prostate-specific membrane antigen in renal cortical tumors. <i>Modern Pathology</i> , 2008, 21, 727-732.  | 2.9 | 42        |
| 316 | Sunitinib therapy in renal cell carcinoma. <i>BJU International</i> , 2008, 101, 1339-1342.  | 1.3 | 18        |
| 317 | Phase II Trial of Pegylated Interferon- $\alpha$ 2b in Patients with Advanced Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, 25-30.   | 0.9 | 20        |
| 318 | Current Algorithms and Prognostic Factors in the Treatment of Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2008, 6, S7-S13.   | 0.9 | 37        |
| 319 | Infectious Complications from High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Metastatic Germ Cell Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 595-600. | 2.0 | 6         |
| 320 | Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. <i>Lancet, The</i> , 2008, 372, 449-456.                                      | 6.3 | 2,848     |
| 321 | Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. <i>Journal of Urology</i> , 2008, 180, 873-878.  | 0.2 | 131       |
| 322 | Systemic Therapy for Metastatic Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2008, 35, 687-701.  | 0.8 | 39        |
| 323 | Stage I Testicular Cancer Management and Necessity for Surgical Expertise. <i>Journal of Clinical Oncology</i> , 2008, 26, 2934-2936.  | 0.8 | 14        |
| 324 | Clinical Outcome and Predictors of Survival in Late Relapse of Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2008, 26, 5524-5529.   | 0.8 | 107       |

| #   | ARTICLE  | IF   | CITATIONS |
|-----|--|------|-----------|
| 325 | Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. <i>Oncologist</i> , 2008, 13, 1084-1096.  | 1.9  | 198       |
| 326 | Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 3763-3769.  | 0.8  | 122       |
| 327 | Medical Treatment of Advanced Testicular Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 672.   | 3.8  | 307       |
| 328 | Economic Evaluation of Sunitinib Malate for the First-Line Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2008, 26, 3995-4000.  | 0.8  | 74        |
| 329 | Is high-dose chemotherapy effective in patients with relapsed or refractory germ cell tumors?. <i>Nature Reviews Urology</i> , 2008, 5, 78-79.   | 1.4  | 1         |
| 330 | Carbonic Anhydrase IX Expression in Clear Cell Renal Cell Carcinoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 377-382.  | 2.1  | 96        |
| 331 | Signal Transduction Inhibitors in Renal Cell Carcinoma. , 2008, , 399-413.   |      | 0         |
| 332 | Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 2271-2281.   | 13.9 | 3,490     |
| 333 | Improved Clinical Outcome in Recent Years for Men With Metastatic Nonseminomatous Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 5603-5608.   | 0.8  | 92        |
| 334 | Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin Plus Etoposide in Previously Treated Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 26, 85-90.   | 0.8  | 119       |
| 335 | Re: Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib. <i>Journal of the National Cancer Institute</i> , 2007, 99, 974-975.   | 3.0  | 26        |
| 336 | Nonrandomized Comparison of Primary Chemotherapy and Retroperitoneal Lymph Node Dissection for Clinical Stage IIA and IIB Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5597-5602.  | 0.8  | 114       |
| 337 | Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Clinical Oncology</i> , 2007, 25, 4365-4369.  | 0.8  | 132       |
| 338 | Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 3958-3964.   | 0.8  | 124       |
| 339 | Phase III Randomized Trial of Conventional-Dose Chemotherapy With or Without High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Rescue As First-Line Treatment for Patients With Poor-Prognosis Metastatic Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 247-256. | 0.8  | 326       |
| 340 | Targeted drugs for metastatic renal cell carcinoma. <i>Lancet, The</i> , 2007, 370, 2071-2073.   | 6.3  | 79        |
| 341 | Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. <i>Lancet Oncology, The</i> , 2007, 8, 975-984.  | 5.1  | 428       |
| 342 | Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2007, 356, 115-124.  | 13.9 | 5,409     |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 343 | Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. <i>Journal of Clinical Oncology</i> , 2007, 25, 1033-1037.   | 0.8 | 99        |
| 344 | Incidence of Disease Outside Modified Retroperitoneal Lymph Node Dissection Templates in Clinical Stage I or IIA Nonseminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2007, 177, 937-943.                                       | 0.2 | 97        |
| 345 | Immunohistochemical Expression of Hypoxia Inducible Factor-1 $\alpha$ and its Downstream Molecules in Sarcomatoid Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 177, 1258-1263.   | 0.2 | 70        |
| 346 | Sunitinib Efficacy Against Advanced Renal Cell Carcinoma. <i>Journal of Urology</i> , 2007, 178, 1883-1887.   | 0.2 | 186       |
| 347 | Interferon- $\gamma$ Resistance Associated Genes in Renal Cell Carcinoma Identified by Expression Profiling. <i>Journal of Urology</i> , 2007, 177, 1264-1268.  | 0.2 | 4         |
| 348 | Adjuvant Chemotherapy for Stage II Nonseminomatous Germ Cell Tumors. <i>Urologic Clinics of North America</i> , 2007, 34, 179-185.  | 0.8 | 7         |
| 349 | Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. <i>Journal of Translational Medicine</i> , 2007, 5, 32.                     | 1.8 | 297       |
| 350 | Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. <i>Scientific World Journal, The</i> , 2007, 7, 768-778.   | 0.8 | 43        |
| 351 | Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour. <i>BJU International</i> , 2007, 99, 993-997.  | 1.3 | 33        |
| 352 | Phase II Trial of ixabepilone in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2007, 25, 487-490.   | 1.2 | 21        |
| 353 | 830: Clinical Outcome Following Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Men with CII Non-Seminomatous Germ Cell Tumors and a Radiographically Normal Retroperitoneum. <i>Journal of Urology</i> , 2007, 177, 277-277.           | 0.2 | 9         |
| 354 | Sunitinib malate for the treatment of solid tumours: a review of current clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 553-561.   | 1.9 | 108       |
| 355 | Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node Dissection. <i>Journal of Urology</i> , 2006, 176, 100-104.   | 0.2 | 70        |
| 356 | A brief symptom index for advanced renal cell carcinoma. <i>Health and Quality of Life Outcomes</i> , 2006, 4, 68.  | 1.0 | 10        |
| 357 | Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 16-24. | 0.8 | 1,590     |
| 358 | Long-term response with sunitinib for metastatic renal cell carcinoma. <i>Urology</i> , 2006, 68, 672.e19-672.e20.  | 0.5 | 8         |
| 359 | Renal cell carcinoma local recurrences: impact of surgical treatment and concomitant metastasis on survival. <i>BJU International</i> , 2006, 97, 933-938.  | 1.3 | 71        |
| 360 | Targeted Therapy for Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5601-5608.  | 0.8 | 336       |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 361 | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. <i>Investigational New Drugs</i> , 2006, 24, 543-546.                          | 1.2 | 136       |
| 362 | Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. <i>Cancer</i> , 2006, 107, 1793-1800.  | 2.0 | 86        |
| 363 | Treatment outcome for metastatic papillary renal cell carcinoma patients. <i>Cancer</i> , 2006, 107, 2617-2621.   | 2.0 | 87        |
| 364 | Medullary Renal Cell Carcinoma and Response to Therapy With Bortezomib. <i>Journal of Clinical Oncology</i> , 2006, 24, e14-e14.  | 0.8 | 47        |
| 365 | Renal Cell Carcinoma Recurrence After Nephrectomy for Localized Disease: Predicting Survival From Time of Recurrence. <i>Journal of Clinical Oncology</i> , 2006, 24, 3101-3106.                            | 0.8 | 251       |
| 366 | Chemotherapy for Advanced Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 5493-5502.  | 0.8 | 64        |
| 367 | Sunitinib in Patients With Metastatic Renal Cell Carcinoma. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2516.  | 3.8 | 1,111     |
| 368 | Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 7215-7220.  | 3.2 | 159       |
| 369 | Transcriptional Program Associated with IFN- $\gamma$ Response of Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 156-170.   | 0.5 | 2         |
| 370 | Advances in Urologic Oncology: Results Progress From Successful Interdisciplinary Research. <i>Journal of Clinical Oncology</i> , 2006, 24, 5479-5481.  | 0.8 | 1         |
| 371 | 449: The Impact of Residual Extra-Retroperitoneal Masses in Patients with Advanced Non-Seminomatous Germ Cell Testicular Cancer. <i>Journal of Urology</i> , 2006, 175, 145-146.                            | 0.2 | 5         |
| 372 | Testicular Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2006, 4, 1038.  | 2.3 | 16        |
| 373 | IL4 Treatment of Metastatic Renal Cell Carcinoma in 2006 : The Bridge from Yesterday to Tomorrow(IL). <i>Japanese Journal of Urology</i> , 2006, 97, 87.  | 0.0 | 0         |
| 374 | Novel targets and therapies for metastatic renal cell carcinoma. <i>Oncology</i> , 2006, 20, 1745-53; discussion 1756.  | 0.4 | 9         |
| 375 | Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development. <i>BJU International</i> , 2005, 96, 286-290.                  | 1.3 | 51        |
| 376 | Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 6549-6555. | 0.8 | 353       |
| 377 | Incidence of Late-Relapse Germ Cell Tumor and Outcome to Salvage Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 6999-7004.   | 0.8 | 77        |
| 378 | Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2005, 23, 9290-9294.  | 0.8 | 91        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 379 | Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Testicular Cancer: Impact of Patient Selection Factors on Outcome. <i>Journal of Clinical Oncology</i> , 2005, 23, 2781-2788.                            | 0.8 | 185       |
| 380 | A POSTOPERATIVE PROGNOSTIC NOMOGRAM PREDICTING RECURRENCE FOR PATIENTS WITH CONVENTIONAL CLEAR CELL RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2005, 173, 48-51.  | 0.2 | 480       |
| 381 | RETROPERITONEAL LYMPH NODE DISSECTION IN PATIENTS WITH LOW STAGE TESTICULAR CANCER WITH EMBRYONAL CARCINOMA PREDOMINANCE AND/OR LYMPHOVASCULAR INVASION. <i>Journal of Urology</i> , 2005, 174, 557-560.                     | 0.2 | 103       |
| 382 | Late relapse of testicular germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 441-445.   | 0.8 | 36        |
| 383 | Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 454-463.  | 0.8 | 742       |
| 384 | Prognostic Factors for Survival of Patients with Stage IV Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 6302S-6303S.   | 3.2 | 169       |
| 385 | Phase II Trial of Bortezomib for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3720-3725.   | 0.8 | 176       |
| 386 | Innovations and Challenges in Renal Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 6277S-6281S.   | 3.2 | 38        |
| 387 | Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2004, 22, 464-467. | 0.8 | 90        |
| 388 | Phase II Trial of Temozolomide in Patients with Cisplatin-Refractory Germ Cell Tumors. <i>Investigational New Drugs</i> , 2004, 22, 177-179.   | 1.2 | 12        |
| 389 | Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. <i>Annals of Surgical Oncology</i> , 2004, 11, 71-77.   | 0.7 | 244       |
| 390 | Predicting survival of patients with metastatic renal cell carcinoma. <i>Der Urologe</i> , 2004, 43, 135-136.  | 2.0 | 5         |
| 391 | Editorial: Predicting Necrosis After Chemotherapy for Advanced Nonseminomatous Germ Cell Tumor—Surrogate End Points, Decreasing Morbidity and Patient Outcome. <i>Journal of Urology</i> , 2004, 171, 1842-1843.             | 0.2 | 5         |
| 392 | Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. <i>Journal of Nuclear Medicine</i> , 2004, 45, 1412-21.   | 2.8 | 72        |
| 393 | Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 341-345.  | 1.2 | 81        |
| 394 | Phase II trial of anti-epidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2003, 21, 99-101.   | 1.2 | 140       |
| 395 | Recommendations of follow-up after treatment of germ cell tumors. <i>Seminars in Oncology</i> , 2003, 30, 382-389.   | 0.8 | 18        |
| 396 | Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials. <i>Cancer</i> , 2003, 98, 1611-1619.   | 2.0 | 40        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 397 | Prognostic factors and clinical trials of new agents in patients with metastatic renal cell carcinoma. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 46, 33-39.  | 2.0 | 96        |
| 398 | Incidence and Clinical Outcome of Patients with Teratoma in the Retroperitoneum Following Primary Retroperitoneal Lymph Node Dissection for Clinical Stages I and IIA Nonseminomatous Germ Cell Tumors. <i>Journal of Urology</i> , 2003, 170, 1159-1162.         | 0.2 | 56        |
| 399 | Management of recurrence and follow-up strategies for patients with seminoma and selected high-risk groups. <i>Urologic Clinics of North America</i> , 2003, 30, 803-817.   | 0.8 | 13        |
| 400 | Results of Retroperitoneal Lymph Node Dissection for Clinical Stage I and II Pure Embryonal Carcinoma of the Testis. <i>Journal of Urology</i> , 2003, 170, 1155-1158.  | 0.2 | 24        |
| 401 | Long-term follow-up of bilateral sporadic renal tumors. <i>Urology</i> , 2003, 61, 921-925.   | 0.5 | 51        |
| 402 | Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome. <i>Urology</i> , 2003, 62, 732-736.  | 0.5 | 86        |
| 403 | Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. <i>Urology</i> , 2003, 62, 1092-1096.   | 0.5 | 29        |
| 404 | Renal Cell Carcinoma: A Priority Malignancy for Development and Study of Novel Therapies. <i>Journal of Clinical Oncology</i> , 2003, 21, 1193-1194.  | 0.8 | 36        |
| 405 | Poor-Risk Testicular Cancer and High-Dose Chemotherapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 4073-4074.  | 0.8 | 3         |
| 406 | Chemotherapy for Teratoma With Malignant Transformation. <i>Journal of Clinical Oncology</i> , 2003, 21, 4285-4291.   | 0.8 | 211       |
| 407 | Cluster Analysis of p53 and Ki67 Expression, Apoptosis, Alpha-Fetoprotein, and Human Chorionic Gonadotrophin Indicates a Favorable Prognostic Subgroup Within the Embryonal Carcinoma Germ Cell Tumor. <i>Journal of Clinical Oncology</i> , 2003, 21, 2679-2688. | 0.8 | 25        |
| 408 | Prognostic Factors for Metastatic Kidney Cancer. <i>Cancer Treatment and Research</i> , 2003, 116, 139-153.   | 0.2 | 3         |
| 409 | Phase II trial of branched peginterferon- $\alpha$ 2a (40 kDa) for patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1799-1805.  | 0.6 | 46        |
| 410 | Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non-“Clear-Cell Histology. <i>Journal of Clinical Oncology</i> , 2002, 20, 2376-2381.   | 0.8 | 459       |
| 411 | Testicular Seminoma: A Clinicopathologic and Immunohistochemical Study of 105 Cases with Special Reference to Seminomas with Atypical Features. <i>International Journal of Surgical Pathology</i> , 2002, 10, 23-32.   | 0.4 | 84        |
| 412 | Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 289-296.   | 0.8 | 1,357     |
| 413 | Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. <i>Urology</i> , 2002, 60, 1003-1009.   | 0.5 | 128       |
| 414 | ALLELIC LOSS ON CHROMOSOMES 8 AND 9 CORRELATES WITH CLINICAL OUTCOME IN LOCALLY ADVANCED CLEAR CELL CARCINOMA OF THE KIDNEY. <i>Journal of Urology</i> , 2002, 167, 1464-1468.  | 0.2 | 53        |



| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 415 | Salvage Chemotherapy for Patients With Advanced Pure Seminoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 297-301.  | 0.8 | 54        |
| 416 | Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 302-306.  | 0.8 | 111       |
| 417 | Partial nephrectomy: The rationale for expanding the indications. <i>Annals of Surgical Oncology</i> , 2002, 9, 680-687.   | 0.7 | 64        |
| 418 | Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. <i>Investigational New Drugs</i> , 2002, 20, 327-330.   | 1.2 | 68        |
| 419 | Adjuvant chemotherapy for stage II nonseminomatous germ-cell tumors. <i>Urologic Oncology</i> , 2002, 20, 239-243.   | 1.5 | 5         |
| 420 | Partial nephrectomy: The rationale for expanding the indications. , 2002, 9, 680.  |     | 4         |
| 421 | Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. <i>Journal of Urology</i> , 2002, 167, 1464-8.  | 0.2 | 17        |
| 422 | A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2001, 166, 63-67.  | 0.2 | 677       |
| 423 | Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2001, 19, 1312-1319.   | 0.8 | 92        |
| 424 | Low-Volume Nodal Metastases Detected at Retroperitoneal Lymphadenectomy for Testicular Cancer: Pattern and Prognostic Factors for Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 2020-2025.  | 0.8 | 95        |
| 425 | Role of Postchemotherapy Adjunctive Surgery in the Management of Patients With Nonseminoma Arising From the Mediastinum. <i>Journal of Clinical Oncology</i> , 2001, 19, 682-688.  | 0.8 | 99        |
| 426 | Phase II trial of ifofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 2001, 19, 317-320.  | 1.2 | 23        |
| 427 | Randomized Multicenter Phase II Trial of Subcutaneous Recombinant Human Interleukin-12 Versus Interferon- $\alpha$ 2a for Patients with Advanced Renal Cell Carcinoma. <i>Journal of Interferon and Cytokine Research</i> , 2001, 21, 257-263. | 0.5 | 102       |
| 428 | Phase II trial of pyrazoloacridine in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 2000, 18, 265-267.   | 1.2 | 8         |
| 429 | Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 2413-2418.   | 0.8 | 228       |
| 430 | Sequential Dose-Intensive Paclitaxel, Ifosfamide, Carboplatin, and Etoposide Salvage Therapy for Germ Cell Tumor Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 1173-1180.  | 0.8 | 187       |
| 431 | Phase III Trial of Interferon Alfa-2a With or Without 13-cis-Retinoic Acid for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 2972-2980.   | 0.8 | 267       |
| 432 | Effect of Cytokine Therapy on Survival for Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2000, 18, 1928-1935.   | 0.8 | 187       |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 433 | Calvert's Formula for Dosing Carboplatin: Overview and Concerns of Applicability in High-Dose Setting. <i>Journal of the National Cancer Institute</i> , 2000, 92, 1434-1436.   | 3.0  | 12        |
| 434 | Cytokine therapy in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 249-257.   | 0.8  | 24        |
| 435 | Carcinoid tumor of the kidney. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2000, 5, 108-111.   | 0.8  | 45        |
| 436 | SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, 163, 408-417.  | 0.2  | 552       |
| 437 | SYSTEMIC THERAPY FOR RENAL CELL CARCINOMA. <i>Journal of Urology</i> , 2000, , 408.   | 0.2  | 25        |
| 438 | Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. <i>Clinical Pharmacology and Therapeutics</i> , 1999, 65, 615-629. | 2.3  | 34        |
| 439 | Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 2530-2530.   | 0.8  | 1,641     |
| 440 | A phase II study of pyrazoloacridine in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1998, 16, 337-340.  | 1.2  | 4         |
| 441 | TERATOMA WITH MALIGNANT TRANSFORMATION: DIVERSE MALIGNANT HISTOLOGIES ARISING IN MEN WITH GERM CELL TUMORS. <i>Journal of Urology</i> , 1998, 159, 133-138.   | 0.2  | 384       |
| 442 | Surgery for a Post-Chemotherapy Residual Mass in Seminoma. <i>Journal of Urology</i> , 1997, 157, 860-862.  | 0.2  | 157       |
| 443 | Testicular Germ-Cell Cancer. <i>New England Journal of Medicine</i> , 1997, 337, 242-254.   | 13.9 | 832       |
| 444 | A phase II study of 13-cis-retinoic acid in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1997, 15, 353-355.  | 1.2  | 27        |
| 445 | Renal cell carcinoma. <i>Current Problems in Cancer</i> , 1997, 21, 185-232.  | 1.0  | 106       |
| 446 | Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 1996, 335, 865-875.  | 13.9 | 1,747     |
| 447 | all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. <i>Cancer</i> , 1995, 76, 680-686.  | 2.0  | 30        |
| 448 | Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. <i>Cancer</i> , 1995, 76, 824-832.   | 2.0  | 265       |
| 449 | Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. <i>Investigational New Drugs</i> , 1995, 13, 163-165.   | 1.2  | 28        |
| 450 | Phase iii randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. , 1995, 76, 824.   |      | 2         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 451 | Phase II trial of liposomal encapsulated doxorubicin in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 323-325.  | 1.2 | 26        |
| 452 | Phase II trial of topotecan in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1994, 12, 143-145.   | 1.2 | 36        |
| 453 | Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma. <i>Cancer</i> , 1994, 73, 1892-1894.  | 2.0 | 33        |
| 454 | Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. <i>Cancer</i> , 1994, 73, 2520-2526.  | 2.0 | 70        |
| 455 | Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. <i>Cancer</i> , 1994, 73, 2843-2852.   | 2.0 | 33        |
| 456 | Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor a randomized trial. <i>Cancer</i> , 1993, 71, 2515-2521. | 2.0 | 51        |
| 457 | Optimal treatment for advanced seminoma?. <i>Cancer</i> , 1993, 72, 3-4.  | 2.0 | 16        |
| 458 | Suramin for germ cell tumors. In vitro growth inhibition and results of a phase II trial. <i>Cancer</i> , 1993, 72, 3313-3317.  | 2.0 | 26        |
| 459 | Acute Nonlymphocytic Leukemia in Germ Cell Tumor Patients Treated With Etoposide-Containing Chemotherapy. <i>Journal of the National Cancer Institute</i> , 1993, 85, 60-62.  | 3.0 | 112       |
| 460 | ROLE OF ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE II NONSEMINOMATOUS GERM-CELL TUMORS. <i>Urologic Clinics of North America</i> , 1993, 20, 111-116.   | 0.8 | 16        |
| 461 | Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT. <i>Investigational New Drugs</i> , 1992, 10, 327-330.                    | 1.2 | 13        |
| 462 | High-dose chemotherapy and autologous bone marrow rescue for patients with refractory germ cell tumors. Early intervention is better tolerated. <i>Cancer</i> , 1992, 69, 550-556.  | 2.0 | 105       |
| 463 | Surgical resection of solitary metastases after chemotherapy in patients with nonseminomatous germ cell tumors and elevated serum tumor markers. <i>Cancer</i> , 1992, 70, 2354-2357.   | 2.0 | 88        |
| 464 | Salvage chemotherapy for patients with germ cell tumors. The memorial sloan-kettering cancer center experience (1979-1989). <i>Cancer</i> , 1991, 67, 1305-1310.  | 2.0 | 127       |
| 465 | Phase II trial of Didemnin B in patients with advanced renal cell carcinoma. <i>Investigational New Drugs</i> , 1990, 8, 391-2.   | 1.2 | 17        |
| 466 | Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors. <i>Cancer</i> , 1990, 65, 2465-2470.  | 2.0 | 37        |
| 467 | The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors. <i>Cancer</i> , 1990, 66, 2476-2481.   | 2.0 | 119       |